Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus [clinicaltrials:NCT00328536]
Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus [clinicaltrials:NCT00328536]
Bio2RDF identifier
NCT00328536
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00328536
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
The purpose of the stud ...... ith type 2 diabetes mellitus.
brief title [clinicaltrials_vocabulary:brief-title]
Omacor for the Treatment of Va ...... With Type 2 Diabetes Mellitus
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2008-11-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Patients with type 2 di ...... after a
high fat meal.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2006-05-19T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
endothelial dysfunction
flow-mediated vasodilatation
omega-3 fatty acids
postprandial state
type 2 diabetes mellitus
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2009-05-07T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00328536
official title [clinicaltrials_vocabulary:official-title]
Effects of Treatment With Omac ...... With Type 2 Diabetes Mellitus
org study id [clinicaltrials_vocabulary:org-study-id]
OMACOR-D-01/06
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2008-11-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2007-04-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2009-05-01T00:00:00Z
identifier
clinicaltrials:NCT00328536
title
Omacor for the Treatment of Va ...... With Type 2 Diabetes Mellitus
@en
type
label
Omacor for the Treatment of Va ...... s [clinicaltrials:NCT00328536]
@en